Latest News
MariTide Approval: When Could Amgen’s Obesity Drug Reach Patients?
MariTide approval cannot be decided until Amgen files, and a search on 5 November 2026 found no filing announcement. BioSpace reported on 4 November 2026 that the first Phase 3 data are expected in 2027. The same report gave no regulatory filing timeline. Amgen’s...
Latest News
BBP-418 Approval: When Could BridgeBio’s First LGMD Drug Launch?
BBP-418 approval is due to be decided by the US Food and Drug Administration (FDA) by 27 November 2026. That is the target action date for BridgeBio’s oral treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). BioSpace reported on 2 November 2026 that...
When AI Writes Medical Device Requirements, What Does It Miss?
Artificial intelligence is making its way into nearly every stage of medical device development, including one of the most foundational activities: defining product requirements. With a well-structured prompt, AI-generated requirements, spanning user needs, software...
ULP Launches Founders’ Bench Award for Ophthalmology Innovation
University Lab Partners Launches Inaugural Founders’ Bench Award to Accelerate Ophthalmology Innovation Bausch + Lomb joins as founding corporate partner; UCI’s Gavin Herbert Eye Institute serves as academic partner University Lab Partners (ULP) today announced the...
The Weakest Link in Your Manuscript May Be the Image You Overlooked
Image duplication, one of the most common image integrity problems in published research, can result from an inadvertent mix-up during figure preparation, reuse that has not been clearly explained, or deliberate fabrication. A 2025 analysis of the Retraction Watch...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Who Owns Ilofotase Alfa Now? Inside Ambrose’s AM-Pharma Deal
Ilofotase alfa now belongs to Ambrose Healthcare, a UK-headquartered rare disease company. On 20 October 2026, Ambrose said it had acquired 100 per cent of the shares of AM-Pharma. The Dutch company, based in Utrecht, developed the drug. The deal is complete rather...
RNA-LNP Development: Creative Biolabs Links Design, Formulation & Analysis
RNA delivery research is moving beyond conventional lipid nanoparticle (LNP) formulation toward a more systematic understanding of how lipid chemistry, particle organization, and intracellular trafficking influence delivery performance. As researchers confront...
Bepirovirsen NHS Access: Will UK Hepatitis B Patients Get Hibsago?
Bepirovirsen NHS access is undecided, because the drug has no UK marketing authorisation. GSK said the US FDA approved bepirovirsen, branded Hibsago, for chronic hepatitis B on 20 October 2026. NHS patients cannot expect routine access until the MHRA authorises it and...
Pediatric Eye Injuries: Severity, Referral and Permanent Vision Loss
A child's vision is one of their most important developmental assets. Sight shapes how children learn, play, read, and connect with the world around them, and unlike many other aspects of health, vision loss caused by pediatric eye injuries can have consequences that...
Who Notices When a Clinical Model Drifts?
Most clinical prediction tools get one big exam. Someone pulls a retrospective cohort, runs the numbers, shows a committee a curve, and the tool goes live. After that the exam rarely gets repeated, so model drift can go unnoticed. The emergency department keeps...
UK Lab Space in 2026: Record Vacancy, Regional Squeeze
UK lab space demand reached a record in 2026. So did UK lab space vacancy. CoStar data shows national laboratory vacancy hit a record 14.3% in the second quarter of 2026. That is more than double the level of two years earlier. Yet some regional science parks say...
Dostarlimab Rectal Cancer: Will the NHS Offer It Outside Wales?
The NHS has made no UK-wide decision on dostarlimab rectal cancer treatment, as of 20 October 2026. The US Food and Drug Administration (FDA) granted accelerated approval on 19 October 2026. The product is GSK’s Jemperli (dostarlimab). Wales has supported off-label...
When the AI Inside a Medical Device Belongs to Someone Else
Medical device manufacturers have long relied on third-party technology. Generative AI, however, presents new challenges for manufacturers of AI medical devices, who may have little influence over how the external model is developed. The technology may be outside of...
Redrawing the Limits of “Undruggable” Proteins
For most of modern target-based drug discovery's history, many biologically important targets have been sidelined as undruggable proteins: structural scaffolds and transcription factors with no active site to inhibit, proteins presenting flat surfaces with no pocket...
Roche Hansoh ADC Deal: What Does Roche Get for $400 Million?
The Roche Hansoh ADC deal gives Roche rights outside Greater China to a portfolio of early antibody-drug conjugates. In return, Roche pays $400 million upfront and $110 million on the first anniversary. Hansoh Pharmaceutical announced the strategic collaboration and...
When Will Merck KGaA’s Silence Therapeutics Acquisition Close?
Merck KGaA, Darmstadt, Germany, expects the Silence Therapeutics acquisition to close in the first quarter of 2027. It will pay $20.00 in cash per American depositary share (ADS). That values Silence at about $1.3 billion. The companies announced the deal on 19...
Function Is the Endpoint: Why Aging Research Should Track Reserve
Ask older adults what they fear about aging and few of them name a number. They name the stairs. They name the low chair they cannot get out of, the groceries they cannot carry in from the car, the day they need someone's help to stay at home. That is the question...
Who Owns Ilofotase Alfa Now? Inside Ambrose’s AM-Pharma Deal
Ilofotase alfa now belongs to Ambrose Healthcare, a UK-headquartered rare disease company. On 20 October 2026, Ambrose said it had acquired 100 per cent of the shares of AM-Pharma. The Dutch company, based in Utrecht, developed the drug. The deal is complete rather...
RNA-LNP Development: Creative Biolabs Links Design, Formulation & Analysis
RNA delivery research is moving beyond conventional lipid nanoparticle (LNP) formulation toward a more systematic understanding of how lipid chemistry, particle organization, and intracellular trafficking influence delivery performance. As researchers confront...
Bepirovirsen NHS Access: Will UK Hepatitis B Patients Get Hibsago?
Bepirovirsen NHS access is undecided, because the drug has no UK marketing authorisation. GSK said the US FDA approved bepirovirsen, branded Hibsago, for chronic hepatitis B on 20 October 2026. NHS patients cannot expect routine access until the MHRA authorises it and...
Pediatric Eye Injuries: Severity, Referral and Permanent Vision Loss
A child's vision is one of their most important developmental assets. Sight shapes how children learn, play, read, and connect with the world around them, and unlike many other aspects of health, vision loss caused by pediatric eye injuries can have consequences that...
Who Notices When a Clinical Model Drifts?
Most clinical prediction tools get one big exam. Someone pulls a retrospective cohort, runs the numbers, shows a committee a curve, and the tool goes live. After that the exam rarely gets repeated, so model drift can go unnoticed. The emergency department keeps...
UK Lab Space in 2026: Record Vacancy, Regional Squeeze
UK lab space demand reached a record in 2026. So did UK lab space vacancy. CoStar data shows national laboratory vacancy hit a record 14.3% in the second quarter of 2026. That is more than double the level of two years earlier. Yet some regional science parks say...
Dostarlimab Rectal Cancer: Will the NHS Offer It Outside Wales?
The NHS has made no UK-wide decision on dostarlimab rectal cancer treatment, as of 20 October 2026. The US Food and Drug Administration (FDA) granted accelerated approval on 19 October 2026. The product is GSK’s Jemperli (dostarlimab). Wales has supported off-label...
When the AI Inside a Medical Device Belongs to Someone Else
Medical device manufacturers have long relied on third-party technology. Generative AI, however, presents new challenges for manufacturers of AI medical devices, who may have little influence over how the external model is developed. The technology may be outside of...
Redrawing the Limits of “Undruggable” Proteins
For most of modern target-based drug discovery's history, many biologically important targets have been sidelined as undruggable proteins: structural scaffolds and transcription factors with no active site to inhibit, proteins presenting flat surfaces with no pocket...
Roche Hansoh ADC Deal: What Does Roche Get for $400 Million?
The Roche Hansoh ADC deal gives Roche rights outside Greater China to a portfolio of early antibody-drug conjugates. In return, Roche pays $400 million upfront and $110 million on the first anniversary. Hansoh Pharmaceutical announced the strategic collaboration and...
When Will Merck KGaA’s Silence Therapeutics Acquisition Close?
Merck KGaA, Darmstadt, Germany, expects the Silence Therapeutics acquisition to close in the first quarter of 2027. It will pay $20.00 in cash per American depositary share (ADS). That values Silence at about $1.3 billion. The companies announced the deal on 19...
Function Is the Endpoint: Why Aging Research Should Track Reserve
Ask older adults what they fear about aging and few of them name a number. They name the stairs. They name the low chair they cannot get out of, the groceries they cannot carry in from the car, the day they need someone's help to stay at home. That is the question...
Featured Articles
Further News
An AI Study Without Its Data Is Fiction
Why publish the data at all? My answer comes from my own work. We ran our study not with one AI agent but with several, and later it turned out that the numbers did not match. Without validated AI study data, data that the author answers for in front of the scientific...
Weekly News Roundup | 19 October 2026
Life science news 19 October 2026: three licensing deals, three FDA approvals and two MHRA announcements. Gilead Sciences signed a T-cell engager deal worth up to $1.875bn with Vir Biotechnology. Roche licensed an ALK7 obesity candidate from Rona Therapeutics. The...
FDA Rare Disease Framework: What Will It Change for Developers?
The FDA rare disease framework has not yet changed any rule or approval standard. The agency announced it on 14 October 2026 as an initiative, backed by a white paper. It promises evidence expectations tailored to each rare disease, but it sets no timetable. A public...
Clinical Trial Results 16 October 2026
The clinical trial results 16 October 2026 cover neuroendocrine tumours, bladder, head and neck cancers, pulmonary fibrosis and social anxiety. RayzeBio’s RYZ101 met its primary endpoint at interim analysis in gastroenteropancreatic neuroendocrine tumours. The FDA...
In Vivo Gene Editing Nears Its First FDA Decision: What the Data Shows
In vivo gene editing now has a fixed regulatory date. In April 2026, Intellia Therapeutics reported Phase 3 results for lonvo-z, a therapy that edits DNA inside the body. The company described the result as a global first for in vivo gene editing. In September, the US...
Anktiva NHS Access: Can UK Patients Get It for Bladder Cancer?
Anktiva NHS access has no NICE recommendation behind it. The medicine holds a UK licence for BCG-unresponsive bladder cancer. However, NICE ended its appraisal in June 2026 because ImmunityBio did not submit evidence. The question matters again because of a US...
Cresset’s Flare AI Client Turns Hours of Work into Minutes
Scientists can now connect company-approved AI providers such as Claude Code and GitHub Copilot directly to Flare, helping teams set up, execute, and analyze complex computational chemistry workflows in minutes not hours. CAMBRIDGE, UK, 6 October 2026 Drug discovery...
The National Priority Voucher: Inside the FDA’s Shortest Review Pathway
Last updated: 15 October 2026. Programme facts checked against FDA sources on that date. A national priority voucher can cut an FDA drug review from around ten months to one or two. The Commissioner’s National Priority Voucher (CNPV) is an FDA pilot programme rather...
Bispecific T-Cell Engagers in Refractory Autoimmune Disease
Bispecific T-cell engagers, originally developed to redirect immune responses against cancer, are being investigated as potential therapeutic candidates for treatment-refractory autoimmune connective tissue diseases. A 2026 study published in Nature Medicine reported...
Icotrokinra NHS Access: Will the Oral Psoriasis Pill Reach Patients?
Icotrokinra NHS access has no published timetable. As of 14 October 2026, LSDN searches found no UK marketing authorisation for icotrokinra. The drug is approved as Icotyde in the US and EU. The European Commission authorisation was announced on 21 September 2026....
When Familiar Is Not Documented: Mandatory GRAS and Traditional Botanicals
Longan was a familiar food in the home I grew up in. It was a tasty summer fruit we ate in southern China, much like an American family might think of mango. Years later, when I started making beverages in St. Louis, I used longan in a hydration drink, well before FDA...
Medicine Does Not Run on Blood Alone
Prevention-first urine diagnostics will depend not only on how accurately we can measure disease, but on how often and how easily people can be tested. Blood is medicine's default diagnostic medium for good reasons. It circulates through the whole body, carries a...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.